Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

NeuroPace (NPCE) EBITDA Margin (2020 - 2025)

NeuroPace has reported EBITDA Margin over the past 6 years, most recently at 6.65% for Q4 2025.

  • Quarterly results put EBITDA Margin at 6.65% for Q4 2025, up 1037.0% from a year ago — trailing twelve months through Dec 2025 was 16.34% (up 1411.0% YoY), and the annual figure for FY2025 was 16.34%, up 1078.0%.
  • EBITDA Margin for Q4 2025 was 6.65% at NeuroPace, up from 9.51% in the prior quarter.
  • Over the last five years, EBITDA Margin for NPCE hit a ceiling of 6.65% in Q4 2025 and a floor of 129.01% in Q2 2022.
  • Median EBITDA Margin over the past 5 years was 52.25% (2023), compared with a mean of 57.45%.
  • Biggest five-year swings in EBITDA Margin: crashed -6158bps in 2022 and later soared 7375bps in 2023.
  • NeuroPace's EBITDA Margin stood at 100.01% in 2021, then rose by 15bps to 85.39% in 2022, then soared by 60bps to 34.42% in 2023, then soared by 51bps to 17.02% in 2024, then soared by 61bps to 6.65% in 2025.
  • The last three reported values for EBITDA Margin were 6.65% (Q4 2025), 9.51% (Q3 2025), and 29.01% (Q2 2025) per Business Quant data.